QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

Help viewing high resolution images Return to article

Fig. 2. RAMP subtype expression does not alter the DH31-R pharmacological profile. HEK-293 cells were transfected with CG17415, CRE-luc and either no RAMP DNA (hatched), RAMP1 (filled) or RAMP2 (unfilled) (at a ratio of 5:1:1 CG17415: RAMP:CRE-luc), but without RCP. Value are means ± S.E.M. from six wells (drawn from two replicate experiments) and expressed as a percentage of vehicle-treated cells. Peptides were all tested at 1 µmol l^–1 concentrations and only DH₃₁-treated cells showed significant increases in luciferase activity levels as compared to controls. Dromyosuppressin (DMS), adipokinetic hormone (AKH), crustacean cardioactive peptide (CCAP), ecdysis triggering hormone (ETH), and pigment dispersing factor (PDF) were purchased from Multiple Peptide Systems (San Diego, CA, USA). Allatostatin A (AstA), allatostatin C (AstC) and DPKQDFMRFamide (FMRF) were purchased from BACHEM (King of Prussia, PA, USA). Proctolin (PROC) and corazonin (CRZ) were purchased from Sigma (Saint Louis, MO, USA). Diuretic hormone 31 (DH₃₁) was from batch the synthesis of which has been reported previously (Coast et al., 2001). Diuretic hormone 44 (DH₄₄) was synthesized by Syngenta Biotechnology (Research Triangle Park, NC, USA) and leucokinin (LK) were purchased from Invitrogen. Allatostatin B (AstB) was provided by Jan Veenstra, NPF by Joe Crim, Accessory Peptide 99B (SP) by Erik Kubli, ITP, PK2, and hugin peptides by Michael Adams, IPNa and MTYa by Liliane Schoofs, and amnesiac (AMN) peptide from Scott Waddell.

Return to article